4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report

      research-article
      1 , * , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 12 , 16 , 17 , 18 , 5 , 6 , 19 , 20 , 5 , 6 , 5 , 6 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28
      Transplantation and cellular therapy
      Chronic graft-versus-host, disease, Allogeneic hematopoietic cell, transplantation, Consensus, Early diagnosis

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Recognition of the earliest signs and symptoms of chronic graft-versus-host disease (GVHD) that lead to severe manifestations remains a challenge. The standardization provided by the National Institutes of Health (NIH) 2005 and 2014 consensus projects has helped improve diagnostic accuracy and severity scoring for clinical trials, but utilization of these tools in routine clinical practice is variable. Additionally, when patients meet the NIH diagnostic criteria, many already have significant morbidity and possibly irreversible organ damage. The goals of this early diagnosis project are 2-fold. First, we provide consensus recommendations regarding implementation of the current NIH diagnostic guidelines into routine transplant care, outside of clinical trials, aiming to enhance early clinical recognition of chronic GVHD. Second, we propose directions for future research efforts to enable discovery of new, early laboratory as well as clinical indicators of chronic GVHD, both globally and for highly morbid organ-specific manifestations. Identification of early features of chronic GVHD that have high positive predictive value for progression to more severe manifestations of the disease could potentially allow for future pre-emptive clinical trials.

          Related collections

          Most cited references142

          • Record: found
          • Abstract: not found
          • Article: not found

          Interpretative strategies for lung function tests.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

            The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Reliability and validity of the Ocular Surface Disease Index.

              To evaluate the validity and reliability of the Ocular Surface Disease Index (OSDI) questionnaire. Participants (109 patients with dry eye and 30 normal controls) completed the OSDI, the National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), the McMonnies Dry Eye Questionnaire, the Short Form-12 (SF-12) Health Status Questionnaire, and an ophthalmic examination including Schirmer tests, tear breakup time, and fluorescein and lissamine green staining. Factor analysis identified 3 subscales of the OSDI: vision-related function, ocular symptoms, and environmental triggers. Reliability (measured by Cronbach alpha) ranged from good to excellent for the overall instrument and each subscale, and test-retest reliability was good to excellent. The OSDI was valid, effectively discriminating between normal, mild to moderate, and severe dry eye disease as defined by both physician's assessment and a composite disease severity score. The OSDI also correlated significantly with the McMonnies questionnaire, the National Eye Institute Visual Functioning Questionnaire, the physical component summary score of the Short Form-12, patient perception of symptoms, and artificial tear usage. The OSDI is a valid and reliable instrument for measuring the severity of dry eye disease, and it possesses the necessary psychometric properties to be used as an end point in clinical trials.
                Bookmark

                Author and article information

                Journal
                101774629
                50262
                Transplant Cell Ther
                Transplant Cell Ther
                Transplantation and cellular therapy
                2666-6375
                2666-6367
                30 December 2021
                July 2021
                09 April 2021
                31 January 2022
                : 27
                : 7
                : 545-557
                Affiliations
                [1 ]Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
                [2 ]Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida
                [3 ]Department of Hematology, University Hospitals Leuven and KU Leuven, Leuven, Belgium
                [4 ]St. Anna Children’s Hospital, Children’s Cancer Research Institute, Vienna, Austria
                [5 ]Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
                [6 ]Department of Medicine, University of Washington, Seattle, Washington
                [7 ]Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland
                [8 ]Research & Dermatology Services, Department of Veterans Affairs, Nashville, Tennessee
                [9 ]Vanderbilt Dermatology Translational Research Clinic, Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee
                [10 ]Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
                [11 ]Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida
                [12 ]Department of Ophthalmology, University of Illinois at Chicago, Chicago, Illinois
                [13 ]Division for Dry-Eye Disease and Ocular GVHD, Department of Ophthalmology, Medical Faculty and University Hospital, University of Cologne, Cologne, Germany
                [14 ]Department of Ophthalmology, Massachusetts Eye and Ear, Harvard University, Boston, Massachusetts
                [15 ]Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan
                [16 ]ImmunEyez LLC, Irvine, California
                [17 ]Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
                [18 ]Pediatric Blood and Marrow Transplantation, Department of Pediatric Oncology-Hematology-BMT, CancerCare Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada
                [19 ]Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota
                [20 ]Pediatric Hematology/Oncology/BMT, BC Children’s Hospital, Vancouver, British Columbia, Canada
                [21 ]Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
                [22 ]Department of Internal Medicine III, University Hospital of Regensburg, Regensburg, Germany
                [23 ]Department of Microbiology and Immunology, Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina
                [24 ]Department of Pediatrics, Division of Blood & Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota
                [25 ]Division of Hematological Malignancies and Cellular Therapy, Duke University Department of Medicine, Duke Cancer Institute, Durham, North Carolina
                [26 ]Hematology Transplantation, AP-HP Saint Louis Hospital & University of Paris, INSERM U976, Paris, France
                [27 ]Clinical Division of Hematology, Medical University of Graz, Graz, Austria
                [28 ]Division of Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, Massachusetts
                Author notes

                Contributors: John Levine, MD, Mount Sinai Hospital; Paul Carpenter, BSc, MBBS, Fred Hutchinson Cancer Research Center; Joycelyn Palmer, PhD, City of Hope; Tim Randolph, PhD, Fred Hutchinson Cancer Research Center. Ophthalmology:Sandeep Jain, MD, University of Illinois; Philipp Steven, MD, University of Cologne; Zhonghui Lou, MD, PhD, Massachusetts General Hospital; Yoko Ogawa, MD, PhD, Keio University School of Medicine; Michael Stern, PhD, Purdue Biological Sciences Committee. Pulmonary: Gregory Yanik, MD, University of Michigan; Guang-Shing Cheng, MD, Fred Hutchinson Cancer Research Center. Dermatology: Edward Cowen, MD, MHSc, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH.

                [* ]Correspondence and reprint requests: Carrie L. Kitko, MD, 2220 Pierce Avenue, 386 Preston Research Building, Nashville, TN 37232-6310, USA. carrie.l.kitko@ 123456vumc.org (C.L. Kitko).
                Article
                VAPA1757220
                10.1016/j.jtct.2021.03.033
                8803210
                33839317
                4e7bb79e-c5e9-4342-8296-5eacfe5cadf6

                This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/)

                History
                Categories
                Article

                chronic graft-versus-host,disease,allogeneic hematopoietic cell,transplantation,consensus,early diagnosis

                Comments

                Comment on this article